

Final Terms dated 28th December 2016

HELIX SCC PLC (the "**Issuer**")
(incorporated as a public limited liability company (plc) under the laws of Malta)

400 Securities (the "**Securities**") issued on the 28th December 2016 pursuant to the Issuer's Offering Programme for the issuance of asset backed securities and linked to Securitisation Assets comprised in the Finsion Life Cell
Issue Price: 125,000 USD per Security

This document constitutes the final terms of the Securities (the "**Final Terms**") described herein for the purposes of Article 5.4 of the Prospectus Directive and is prepared in connection with the Issuer's Offering Programme for the issuance of asset backed securities. These Final Terms are supplemental to and should be read in conjunction with the Base Prospectus dated the 1st November 2016, which constitutes a base prospectus (the "**Base Prospectus**") for the purpose of the Prospectus Directive. Full information on the Issuer and the offer of the Securities is only available on the basis of the combination of these Final Terms and the Base Prospectus.

The Base Prospectus is available for viewing at www.helix-scc.com and during normal business hours at the registered office of the Issuer and copies may be obtained from such office.

Words and expressions defined in the Base Prospectus and not defined in this document shall bear the same meanings when used herein.

The Issuer has obtained all necessary consents, approvals and authorisations which are necessary in Malta at the date of these Final Terms in connection with the issue of the Securities. The Directors have approved the creation of the Finsion Life Cell by resolution in writing executed on the 6th December 2016. The Directors have also approved the issue of the Securities in the course of a securitisation transaction and the allocation of the proceeds of the issue to the Cellular Assets attributable to the Finsion Life Cell by resolution in writing executed on the 6th December 2016. The issue of these Final Terms was authorised by a resolution of the Directors approved on the 28th October 2016.

PART A – CONTRACTUAL TERMS

By subscribing to the Securities or otherwise acquiring the Securities, the Investor expressly acknowledges and accepts that the Issuer: (i) acts in compliance with the Securitisation Act and the Regulations; and (ii) has created a specific Linked Cell ("the Finsion Life Cell") in respect of the Securities to which all assets, rights, claims and agreements relating to the Securities will be allocated.

Furthermore, the Investor acknowledges and accepts that it only has recourse to the assets of the Finsion Life Cell and not to the assets allocated to other Cells created by the Issuer or to any other non-Cellular Assets of the Issuer. The Investor accordingly acknowledges and accepts that once all the assets allocated to the Finsion Life Cell have been realised, it is not entitled to take any further steps against the Issuer to recover any further sums due and the right to receive any such sum shall be extinguished. The Investor hereby accepts not to attach or otherwise seize the assets of the Issuer allocated to the Finsion Life Cell or to other Cells of the Issuer or other assets of the Issuer. In particular, the Investor shall not be entitled to petition or take any other step for the winding-up, liquidation or bankruptcy of the Issuer or the Finsion Life Cell, or any similar insolvency related proceedings – to take any such action would result in a total loss by the Investor of all rights under the Securities.

[Include whichever of the following apply or specify as "Not Applicable" (N/A). Note that the numbering should remain as set out below, even if "Not Applicable" is indicated for individual paragraphs or subparagraphs.]

[When adding any other information in Part A or in relation to disclosure relating to the interests of natural and legal persons involved in the issue/offer in Part B, consideration should be given as to whether such terms or information constitute "significant new factors" and consequently trigger the need for a supplement to the Base Prospectus under Article 16 of the Prospectus Directive, the publication of which would in turn trigger the investors' right to withdraw their acceptances within a 48-

hour time period.]

Provisions Relating to the Securities

1.	Securities Name/Number:	Finsion Life One
2.	Linked Cell:	Finsion Life Cell
3.	Identification Code:	ISIN (TBC)
4.	Currency:	United States Dollar (USD)
5.	Specified Denomination:	125,000 USD per Security
6.	Issue Price:	125,000 USD per Security
7.	Issue Date:	11 th January 2017
8.	Earliest date of admission to trading:	12 th January 2017 (subject to clause 7(vi) of Part B below regarding 'early closing')
9.	Aggregate Nominal Amount:	Up to 50,000,000 USD (up to 400 units at 125,000 USD per unit), from which shall be deducted: (i) the costs of the issue of the Securities; (ii) the Issuer's (<i>pro rata</i>) general administrative costs; (iii) the initial and future ongoing fees payable to Agents, the Advisor, the Clearing System and any other person specified in the Base Prospectus and in these Final Terms; (iv) premiums which may become due and payable by the Issuer on account of any Life Settlement Policies comprised in the Finsion Life Cell; and (v) the costs anticipated in respect of the ultimate dissolution of the Finsion Life Cell.
10.	Maturity Date:	30 th April 2022 (subject to clause 7(vi) of Part B below regarding 'early closing')
11.	Minimum Tradable Amount:	1 unit of 125,000 USD (being the minimum equivalent to €100,000)

Agents and Other Parties

12.	Arranger Fee	0.5% of the nominal settled amount
13.	Banks with which the main accounts relating to the transaction are held:	Sparkasse Bank Malta plc and the Bank of Utah
14.	Other Agent/s & terms of	N/A

appointment:

PART B - OTHER INFORMATION

- | | | |
|----|--|---|
| 1. | Estimate of total expenses related to admission to listing: | €7,000 |
| 2. | Interests of Natural and Legal Persons involved in the Issue: | Save as otherwise disclosed in the Base Prospectus, so far as the Issuer is aware, no person involved in the issue of the Securities has an interest material to the offer. |
| 3. | Significant representations and collaterals given to the Issuer relating to the Securitisation Assets: | N/A |
| 4. | Estimated Net Proceeds and Total Expenses | |
| | (i) Estimated net proceeds: | 50,000,000 USD net of the expenses estimated in paragraph (ii) below. |
| | (ii) Estimated total expenses: | €50,000 |
| 5. | Date of acquisition of Life Settlement Policies: | 11 th January 2017 |
| 6. | Terms and Conditions of the Offer | |
| 7. | (i) Total amount of the issue: | Up to 400 units having a denomination <i>per unit</i> of 125,000 USD |
| | (ii) Minimum Subscription: | 1 unit of 125,000 USD (being the minimum equivalent to €100,000) |
| | (iii) Maximum subscription: | 400 units having an aggregate denomination of 50,000,000 USD |
| | (iv) Offering Period: | The Offering Period shall run on and from the 28 th December 2016 and shall end on the 30 th April 2017. Applications to subscribe for Securities may be made on a Business Day prior to the lapse of the Offering Period.

The Issuer reserves the right for any reason to reduce the number of Securities offered. |
| | (v) Cancellation of the issuance of Securities: | The Issuer reserves the right to cancel the issuance of Securities for reasons beyond its control, such as an Extraordinary Market Disruption, substantial change of the political, financial, economic, legal, monetary or market conditions at national or international level and/or adverse events regarding the financial or commercial position of the Issuer or the Policy |

Originator and/or other relevant events that in the reasonable discretion of the Issuer may be prejudicial to the offer. The issuance of Securities is conditional, amongst other matters, on the Issuer receiving valid subscriptions for Securities amounting to an aggregate subscription value of at least 2,000,000 USD during the Offering Period. In the event that this condition is not satisfied, the Issuer may cancel the issuance of the Securities. In any such case, Investors or prospective Investors who have already paid or delivered subscription monies for Securities will be entitled to reimbursement of such amounts, but will not receive any remuneration that may have accrued in the period between their payment or delivery of subscription monies and such reimbursement.

(vi) Early closing of the subscription of the Securities or reduction in the number of Securities offered:

The Issuer reserves the right for any reason to close the Offering Period early or reduce the number of Securities offered. If the aggregate subscription value of the Securities at any time on any Business Day prior to the lapse of the Offering Period reaches 50,000,000 USD, the Issuer will close the subscription of the Securities at such time on such Business Day, without prior notification. In any such case, Investors or prospective Investors who have already paid or delivered subscription monies for Securities will be entitled to reimbursement of such amounts, but will not receive any remuneration that may have accrued in the period between their payment or delivery of subscription monies and such reimbursement.

(vii) Other conditions to which the offer is subject:

N/A

(viii) Manner in and date on which results of the offer are to be made public:

Within five (5) Business Days from the issue of all Securities or the lapse of the Offering Period, whichever is the earlier, the Issuer shall make an announcement, in accordance with section 3.19 of the Base Prospectus, confirming the number of Securities issued and the Issuer shall notify any relevant authority of such number of Securities issued in accordance with the requirements of the Listing Rules.

(ix) Amount of any expenses and taxes specifically charged to the subscriber or purchaser:

N/A